Evidence map›Paper›PMID 28993792›Full record

ArticlePersonalized medicine2017

The price of whole-genome sequencing may be decreasing, but who will be sequenced?

Deborah A Marshall, Karen V MacDonald, Jill Oliver Robinson, Lisa F Barcellos, Milena Gianfrancesco, Monica Helm, Amy McGuire, Robert C Green, Michael P Douglas, Michael A Goldman and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Personalized medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Deborah A MarshallDepartment of Community Health Sciences, Room 3C56 Health Research Innovation Centre, University of Calgary, Calgary, Alberta, Canada.
Karen V MacDonaldDepartment of Community Health Sciences, Room 3C56 Health Research Innovation Centre, University of Calgary, Calgary, Alberta, Canada.
Jill Oliver RobinsonCenter for Medical Ethics & Health Policy, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, USA.
Lisa F BarcellosDivision of Epidemiology, School of Public Health, University of California, Berkeley, CA, USA.
Milena GianfrancescoDivision of Epidemiology, School of Public Health, University of California, Berkeley, CA, USA.
Monica HelmCenter for Clinical Genetics and Genomics at Providence Health & Services Southern California, 181 South Buena Vista Street - Suite 240, Burbank, CA 91505, USA.
Amy McGuireCenter for Medical Ethics & Health Policy, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, USA.
Robert C GreenDivision of Genetics, Department of Medicine, Brigham & Women's Hospital, Broad Institute & Harvard Medical School, Boston, MA, USA.
Michael P DouglasDepartment of Clinical Pharmacy, Center for Translational & Policy Research on Personalized Medicine (TRANSPERS), University of California, San Francisco, CA, USA.
Michael A GoldmanDepartment of Biology, College of Science & Engineering, San Francisco State University, San Francisco, CA, USA.
Kathryn A PhillipsDepartment of Clinical Pharmacy, Center for Translational & Policy Research on Personalized Medicine (TRANSPERS), University of California, San Francisco, CA, USA.

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Integration of Whole Genome Sequencing into Clinical MedicineU01HG006500 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI GREEN, ROBERT C. · 2012 to 2016
$11.5M
Genome Sequence-Based Screening for Childhood Risk and Newborn IllnessU19HD077671 · NICHD · BRIGHAM AND WOMEN'S HOSPITAL · PI BEGGS, ALAN H., GREEN, ROBERT C. · 2013 to 2018
$6.1M
Risk-Benefit Trade-Offs for Whole Genome SequencingR01HG007063 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILLIPS, KATHRYN A · 2013 to 2016
$2.5M
NCATS NIH HHS UL1 TR000004NHGRI NIH HHS R01 HG007063NHGRI NIH HHS U01 HG006500NICHD NIH HHS U19 HD077671
6 · The paper itself

Abstract

aimSince whole-genome sequencing (WGS) information can have positive and negative personal utility for individuals, we examined predictors of willingness to pay (WTP) for WGS. PATIENTS &

methodsWe surveyed two independent populations: adult patients (n = 203) and college seniors (n = 980). Ordinal logistic regression models were used to characterize the relationship between predictors and WTP.

resultsSex, age, education, income, genomic knowledge and knowing someone who had genetic testing or having had genetic testing done personally were associated with significantly higher WTP for WGS. After controlling for income and education, males were willing to pay more for WGS than females.

conclusionDifferences in WTP may impact equity, coverage, affordability and access, and should be anticipated by public dialog about related health policy.

Indexed as

access to healthcareattitude to healthhealthcare costshuman genomepersonalized medicinewhole genome sequencingwillingness-to-pay

Identifiers

PMID28993792
PMCPMC5629976

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.